1Q22 Galafold® Revenue Growth of 18.5% to $78.7M
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25% and 2.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

07:48pm, Friday, 06'th May 2022 Zacks Investment Research
Aerie (AERI) misses on both earnings and revenues for the first quarter of 2022.

ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates

07:38pm, Friday, 06'th May 2022 Zacks Investment Research
ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow five-fold from the previous quarter's levels.

Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat

07:02pm, Friday, 06'th May 2022 Zacks Investment Research
Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Why Amicus (FOLD) Might Surprise This Earnings Season

12:40pm, Friday, 06'th May 2022 Zacks Investment Research
Amicus (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Amicus (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Karuna Therapeutics (KRTX) Posts Narrower-Than-Expected Q1 Loss

06:47pm, Thursday, 05'th May 2022 Zacks Investment Research
Karuna Therapeutics' (KRTX) first-quarter 2022 earnings beat estimates. Due to lack of marketed products in its portfolio, KRTX did not record any revenues during the quarter.

Allogene (ALLO) Q1 Earnings Beat, Pipeline Progresses Well

06:46pm, Thursday, 05'th May 2022 Zacks Investment Research
Allogene's (ALLO) first-quarter earnings beat estimates. Upon removal of the FDA's clinical hold on its AlloCAR T candidates, ALLO continues to move forward with its pipeline.

Bears are Losing Control Over Amicus Therapeutics (FOLD), Here's Why It's a 'Buy' Now

01:55pm, Thursday, 05'th May 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement
PHILADELPHIA, May 04, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2022 Healthcare Conference

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?

07:00pm, Monday, 02'nd May 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amicus Therapeutics: An Inflection Point In Growth

07:09pm, Wednesday, 27'th Apr 2022
Despite the bear market, Amicus Therapeutics is enjoying aggressive sales growth for its lead medicine, Galafold, for Fabry. By mid-year, you are most likely to see another approval, that is, AT-GAA f
PHILADELPHIA, April 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 9, 2022 at 8:30 a
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE